Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

News Conference News ACC 2016

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Michael O'Riordan

April 07, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Conference News ACC 2015

DEFLECT III: TAVR Neuroprotection Device Safely Reduces Lesion Volume

Yael L. Maxwell

March 16, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

News Conference News ACC 2014

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

Yael L. Maxwell

April 03, 2014

News Conference News ACC 2014

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Yael L. Maxwell

March 29, 2014

News Conference News ACC 2014

Depth, Cusp Stretching Linked to Need for Pacemaker after TAVR

L.A. McKeown

March 29, 2014

News Conference News ACC 2013

German Valve Registry Shows Advantage of Surgery in Lower Risk Patients

L.A. McKeown

March 11, 2013

News Conference News ACC 2012

Study Looks at Long-term Mortality Predictors in TAVR Patients

Jason Kahn

March 27, 2012

Presentation ACC 2012

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

Presenter: Josep Rod?s-Cabau

March 24, 2012

News Conference News ACC 2012

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

March 24, 2012

Advertisement

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

DEFLECT III: TAVR Neuroprotection Device Safely Reduces Lesion Volume

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

ACC/i2 2014: Cardiologists Carefully Consider TAVR, Renal Denervation

TAVR With the CoreValve Device Superior to Surgery at 1 Year

Depth, Cusp Stretching Linked to Need for Pacemaker after TAVR

German Valve Registry Shows Advantage of Surgery in Lower Risk Patients

Study Looks at Long-term Mortality Predictors in TAVR Patients

Long-Term Outcomes Following Transcatheter Aortic Valve Implantation: Insights on Prognostic Factors and Valve Durability from the Canadian Multicenter Experience

ADVANCE: TAVR with CoreValve Safe, Effective at 6 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content